Results 51 to 60 of about 4,484,991 (333)
Nature Communications, 2017 The treatment of progressive multiple sclerosis (MS) is unsatisfactory. One reason is that the drivers of disease, which include iron-mediated neurotoxicity, lymphocyte activity, and oxidative stress, are not simultaneously targeted.
Simon Faissner +10 more
semanticscholar +1 more source
Aging and Cancer, EarlyView.Aging‐associated physiological and molecular alterations pose significant challenges in cancer management among India's elderly. Limited geriatric oncology expertise, financial constraints, and inadequate specialized care exacerbate disparities. Strategic expansion of insurance coverage, integration of palliative care, and infrastructural advancements ...
Nihanthy D. Sreenath +3 more
wiley +1 more source
The Community Safety Net and Prescription Drug Access for Low-Income, Uninsured People [PDF]
, 2006 Examines strategies adopted by hospitals and community health centers to maintain access to affordable brand name and generic prescription drugs.
Anneliese M. Gerland +2 more
core
Profil Disolusi Terbanding Tablet Rifampisin Merek Dan Generik [PDF]
, 2010 This time many of people still to contemn of generic drugs because they regard as quality of generic drugs low more than trademark drugs. This research was proposed to compare dissolution profile of rifampicine tablets trademark (A, B, C) and generic (C,
Kusuma, A. M. (Anjar) +2 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry +16 more
wiley +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the US Food and Drug ...
Fang Wu +17 more
doaj +1 more source
Generic drugs: benefit/risk ratio
Неврология, нейропсихиатрия, психосоматика, 2021 The review discusses the interchangeability of medications, approaches to the registration of original and generic drugs, and types of their equivalence, as well as problems with generics in clinical practice.
E. A. Ushkalova +2 more
doaj +1 more source
A survey of Top 200 Drugs—Inconsistent Practice of Drug Strength Expression for Drugs Containing Salt Forms [PDF]
, 2012 Many ionizable drugs are developed and marketed as salt forms. However, there are no clear US regulatory guidelines on drug strength labeling for salts. The strengths of some drugs are expressed as salts and some as free acids/bases.
Prohotsky, Daniel, Zhao, Fang
core +2 more sources
Arthritis Care &Research, EarlyView.Objective This study aims to describe the frequency and timing of physician referrals to physical therapists (PTs) and other treatments prescribed over 12 months in patients with recent onset of knee osteoarthritis (KOA). The study also aims to identify determinants of early PT referrals.
Samannaaz S. Khoja +4 more
wiley +1 more source
In Silico Methods for Development of Generic Drug–Device Combination Orally Inhaled Drug Products
CPT: Pharmacometrics & Systems Pharmacology, 2019 The development of generic, single‐entity, drug–device combination products for orally inhaled drug products is challenging in part because of the complex nature of device design characteristics and the difficulties associated with establishing ...
Ross L. Walenga +2 more
doaj +1 more source